MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
common stock offerings
$20,877,925
Net cash provided by
financing activities
$20,877,925
Net change in cash
and cash...
$3,469,103
Canceled cashflow
$17,408,822
Stock-based compensation
expense
$4,280,227
Amortization of in-process
research and development
$573,438
Accrued expenses
$503,054
Deferred income tax
expense
$264,240
Issuance of common stock
for services
$107,510
Issuance of common stock
warrant
$68,597
Operating lease liability
$16,373
Net cash used in
operating activities
-$13,008,822
Net cash used in
investing activities
-$4,400,000
Canceled cashflow
$5,813,439
Net loss
-$9,393,889
Accounts receivable, net
of allowances
$4,049,111
License fee payments
$4,400,000
Accounts payable
-$2,672,280
Prepaid expenses
$2,139,797
Inventory
$352,649
Accrued compensation
-$198,052
Amortization (accretion) of
operating lease...
-$16,483
Back
Back
Cash Flow
source: myfinsight.com
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)